A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CDI-988 in Healthy Adults After Challenge With Snow Mountain Virus

Part of paid clinical trials in Decatur, Georgia.

Sponsor: Cocrystal Pharma, Inc.
Study ID: NCT07198139
Phase: PHASE1/PHASE2
Status: Recruiting

Apply to this trial

Conditions

Norovirus

Eligibility Criteria

Sex: ALL
Age: 18 Years - 49 Years
Healthy Volunteers: Accepted

Interventions

CDI-988 — DRUG
Antiviral to treat norovirus
Placebo — DRUG
Matching placebo
Snow Mountain Virus — OTHER
Challenge with Snow Mountain Virus

Study Details

Participants in this study will be given either CDI-988 or placebo orally before receiving a norovirus challenge virus and continuing for 5 days. Participants will not know whether they are getting placebo or CDI-988. The study will evaluate how well CDI-988 compared to placebo can reduce the incidence of clinical symptoms after a challenge with norovirus. The amount of virus in stool samples will be measured over time. Side effects and pharmacokinetics (the amount of CDI-988 in blood) will also be measured.

Key Dates

Start date: Mar 1, 2026
Status verified: Feb 2026
Primary completion: Oct 1, 2026
Completion: Dec 1, 2026

Study Design

Enrollment: 40 participants (estimated)
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Arms

Other: Snow Mountain Virus
Challenge with Snow Mountain Virus
Experimental: Stage 2: Drug CDI-988
Placebo Comparator: Stage 2: Placebo

Primary Outcome Measure

Incidence of norovirus-confirmed disease [ Time Frame: Day 0 to Day 21 ]

Central Contacts

David Huang, MD, PhD
936-577-5770
[email protected]

Locations (1)

Facility	City	State	ZIP	Site coordinators
Hope Clinic of the Emory Vaccine Center	Decatur	Georgia	30030	Veronica Smith 404-712-1370

Find similar trials in Decatur, GA

By research site

Hope Clinic of the Emory Vaccine Center· Decatur, GA